An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia

• Drug: PF-02545920
  
  PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
  Other Name: 5 mg BID
• Drug: Placebo
  
  Placebo BID until the Week 12 visit
• Drug: PF-02545920
  
  PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
  Other Name: 15 mg BID

• Experimental: PF-02545920 (5mg)
  
  Intervention: Drug: PF-02545920
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo
• Experimental: PF-02545920 (15mg)
  
  Intervention: Drug: PF-02545920

Inclusion Criteria:

• Psychiatrically stable subjects with schizophrenia who have had a suboptimal response to current treatment
• Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
• Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

Exclusion Criteria:

• History of seizures or of a condition with risk of seizures.
• Subjects with schizophrenia that have not responded at all to current treatment.
• Pregnant or nursing females, and females of child bearing potential.